The costeffectiveness of intermittent preventive treatment for malaria

Abstract

Background: Intermittent preventive treatment in infants (IPTi) has been shown to decrease clinical malaria by approximately 30 % in the first year of life and is a promising malaria control strategy for Sub-Saharan Africa which can be delivered alongside the Expanded Programme on Immunisation (EPI). To date, there have been limited data on the cost-effectiveness of this strategy using sulfadoxine pyrimethamine (SP) and no published data on cost-effectiveness using other antimalarials. Methods: We analysed data from 5 countries in sub-Saharan Africa using a total of 5 different IPTi drug regimens; SP